← Back to Search

Growth Hormone Releasing Factor

Tesamorelin for Peripheral Nerve Injury

Phase 2
Recruiting
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ulnar nerve laceration at the wrist, repaired primarily
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial is testing whether the drug tesamorelin can help people recover from peripheral nerve injuries faster and better than people who don't take the drug.

Who is the study for?
This trial is for individuals with ulnar nerve injuries at the wrist that have been surgically repaired. It's not suitable for those with a history of certain cancers, uncontrolled diabetes or hypertension, specific pituitary issues, current use of oral contraceptives, pregnancy, drug/alcohol dependence, or psychosocial issues affecting participation.Check my eligibility
What is being tested?
The study tests if tesamorelin can improve recovery after peripheral nerve injury. Participants will be randomly given either tesamorelin or a placebo and monitored monthly for a year to assess motor and sensory function recovery.See study design
What are the potential side effects?
While the side effects are not detailed here, common ones associated with tesamorelin may include joint pain, skin reactions at the injection site, muscle pain, swelling in hands or feet and less commonly hypersensitivity reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had surgery to fix a cut ulnar nerve in my wrist.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
3-point chuck pinch test
Secondary outcome measures
Amplitude of response
Apparent diffusion coefficient (ADC)
Disability of the Arm, Shoulder, and Hand (DASH) score
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Tesamorelin treatmentExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,260 Previous Clinical Trials
14,820,744 Total Patients Enrolled
United States Department of DefenseFED
863 Previous Clinical Trials
227,596 Total Patients Enrolled
Sami Tuffaha, MDStudy DirectorJohns Hopkins University
1 Previous Clinical Trials
90 Total Patients Enrolled

Media Library

Tesamorelin (Growth Hormone Releasing Factor) Clinical Trial Eligibility Overview. Trial Name: NCT03150511 — Phase 2
Peripheral Nerve Injury Research Study Groups: Placebo, Tesamorelin treatment
Peripheral Nerve Injury Clinical Trial 2023: Tesamorelin Highlights & Side Effects. Trial Name: NCT03150511 — Phase 2
Tesamorelin (Growth Hormone Releasing Factor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03150511 — Phase 2
Peripheral Nerve Injury Patient Testimony for trial: Trial Name: NCT03150511 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the enrollment count for this research endeavor?

"Correct. The clinical trial has been documented on the clinicaltrials.gov website since June 1st 2018, and was last updated in December 7th 2021. It is currently searching for 36 participants across two medical sites."

Answered by AI

What end goals are being pursued with this medical research?

"This research venture, evaluated over a timespan of 12 months, aims to measure the Latency of response. Subsidiary objectives include assessing Disability of the Arm, Shoulder and Hand (DASH) score via questionnaire; Michigan Hand Questionnaire score through survey; as well as Apparent diffusion coefficient (ADC), measured by MRI Diffusion Tensor Imaging."

Answered by AI

Has Tesamorelin 2 MG been employed in any other experimental research?

"Presently, there are 4 active clinical trials examining the efficacy of Tesamorelin 2 Milligrams (MG). There is no Phase 3 trial in progress yet. With 8 different sites hosting studies on this compound, Boston Massachusetts has a particularly strong presence among them."

Answered by AI

Is enrollment for this trial still available to qualified participants?

"Affirmative. According to the data on clinicaltrials.gov, this investigation is actively seeking participants and was originally posted on June 1st 2018 before most recently being updated in December 2021. 36 individuals will be recruited across 2 sites for the trial."

Answered by AI

How has Tesamorelin 2 Milligrams (MG) been evaluated for potential health risks?

"Tesamorelin 2 Milligrams (MG) is believed to be relatively safe, as its Phase 2 trial status offers some degree of assurance that there are no major safety concerns. However, efficacy data remains unavailable at this time."

Answered by AI

Who else is applying?

What state do they live in?
Maryland
What site did they apply to?
Jamie Shores
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
1

Why did patients apply to this trial?

I have had nerve compression and injury in my right leg .
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
2018. "Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03150511.
All > Peripheral Neuropathy
~8 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top